<DOC>
	<DOCNO>NCT00266838</DOCNO>
	<brief_summary>The antineoplastic agent Docetaxel ( Taxotere® ) approve treatment patient metastatic locally advanced breast cancer malignancy . There 2 frequently use schedule treatment Docetaxel . Docetaxel administer every 3 week weekly regimen . The efficacy seem similar toxicity profile change . In standard 3-weekly Docetaxel regimen dose-limiting side effect myelosuppression , weekly regimen mild myelosuppression . On hand , weekly Docetaxel side effect rare 3-weekly schedule : epiphora ( = tear eye ) cause dacryostenosis . The underlie mechanism dacryostenosis induce weekly Docetaxel fibrosis lacrimal puncta canaliculus . Docetaxel report secrete lacrimal tear . Direct contact Docetaxel contain tear epithelial lining cause chronic inflammation mucosa ultimately fibrosis narrow part lacrimal outflow system i.e . lacrimal puncta canaliculus . A surgical treatment possible dacryostenosis . In case subtotal stenosis lacrimal canaliculus , silicone intubation canaliculus perform order prevent closure . In case complete stenosis , placement permanent pyrex glass tube Jones require . To knowledge , primary prevention Docetaxel induce dacryostenosis . The rationale randomize double blind interventional study investigate efficacy corticosteroid versus artificial tear topical eye treatment patient weekly Docetaxel regimen prevention dacryostenosis . The dacryotoxic agent Docetaxel lacrimal tear wash away repetitive use eye drop . In addition , eye drop contain corticosteroid anti-inflammatory effect may prevent formation fibrosis . A new treatment protocol investigate . Two different commercially available eye drop compare : dexamethasone sodium phosphate ( Maxidex® , Alcon ) one eye patient artificial tear ( Lacrystat® , Viatris ) eye patient . The study period start topical eye treatment day 1 cycle 1 continue administration chemotherapy , final analysis 26 week .</brief_summary>
	<brief_title>Prevention Docetaxel Induced Dacryostenosis</brief_title>
	<detailed_description />
	<mesh_term>Lacrimal Apparatus Diseases</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients locally advance metastatic breast cancer receive weekly Docetaxel chemotherapy rest week regular time interval . The timing rest week cycle restrict . Examples allow regimen Docetaxel 36 mg/m2 day 1 8 every 3 week ; day 1 , 8 , 15 every 4 week ; day 1 , 8 , 15 , 21 , 28 , 35 , 42 , 49 every 10 week . Dosing rest week modify depend clinical situation , dose intensity least 60 mg/m2 every 3 week 9 week treatment eligibility . Combination chemotherapy ( capecitabine ) allow . Capability administer eye drop ( either patient companion ) . Written informed consent . Age &gt; 18 Systemic criterion : Previous administration Docetaxel . Pregnancy . Eye criterion : Ocular surface , corneal , conjunctival eyelid disease . Soft contact lens wear Glaucoma Lacrimal criterion : Hypersecretion tear : ocular surface , corneal , conjunctival eyelid disease . Functional blockage lacrimal drainage without anatomical obstruction ( facial nerve palsy , displacement low lacrimal punctum lacrimal lake , involutional low eyelid laxity ) . Anatomical obstruction lacrimal drainage system :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Lacrimal Obstruction</keyword>
	<keyword>Epiphora</keyword>
</DOC>